The advent of groundbreaking cancer drugs has significantly improved patient treatment outcomes and survival rates. However, the high cost of these medications poses a considerable financial burden on healthcare systems and patients alike. In recent years, pay-for-performance (P4P) pricing has gained traction as a potential solution to address the affordability and value of cancer drugs.

The nation’s monthslong shortage of highly potent cancer drugs is grinding on, forcing patients and their doctors to face even grimmer realities than that cancer typically presents. Several factors have contributed to the shortage of cancer drugs, and patients are hurting. What’s going on? At the heart of the problem is that US pharma companies have zero interest in manufacturing off-patent cancer drugs. They have sold the rights to foreign companies whose quality control is a huge issue. Here are the other issues.

A “cancer moonshot” refers to an ambitious effort to accelerate progress in cancer research and treatment, drawing inspiration from the determination and focus that drove the United States moon landing in 1969. While eradicating cancer may be a monumental task, significant advancements have been made in understanding and treating various types of cancer.